Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-818 in Relapsed/Refractory T-Cell Lymphoma
NCT03952078Phase 1Active, not recruiting
- Sponsor
- Corvus Pharmaceuticals
- Start
- May 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of soquelitinib in T-cell lymphoma (2 arms), sponsored by Corvus Pharmaceuticals. Primary endpoints: Incidence, nature, and severity of adverse events and Incidence and nature of dose limiting toxicities. Started May 2019; status: active, not recruiting.
02
Drugs
soquelitinib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT03952078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952078.